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Abstract
 Objective—The 1998 and the 2013 guidelines on management of overweight and obesity in 
adults provided algorithms for identification of patients to be treated with weight loss. To date the 
cardiovascular disease (CVD) risk in the groups recommended or not recommended for weight 
loss treatment have not been estimated and compared.
 Methods—Baseline data for the Atherosclerosis Risk in Communities study (ARIC) were 
collected between1987-9 from adults aged 45-64. Black and White men and women free of CVD 
were followed over 22.8 years (median), and 2,907 incident CVD events were recorded.
 Results—The hazard ratios (HRs) adjusted for demographic variables in adults not 
recommended for treatment vs adults recommended for treatment were 0.54 (95% CI: 0.50, 0.59) 
for the 1998 algorithm and 0.63 (95% CI: 0.58, 0.69) for the 2013 algorithm, respectively. No 
gender or ethnic differences were detected when the 2013 algorithm was applied, but using the 
1998 algorithm CVD risk between the groups recommended or not recommended for treatment 
were more pronounced in Black women than in Black men.
 Conclusions—The 2013 algorithm performed similarly in Black and White men and women, 
but did not improve upon the 1998 algorithm in terms of discriminating risk of CVD.
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The 1998 “Clinical Guidelines on the Identification, Evaluation, and Treatment of 
Overweight and Obesity in Adults” sponsored by the National Heart, Lung and Blood 
Institute (NHLBI) had far-reaching impact on the definition and treatment of excess body 
weight. The report established body mass index (BMI) cutoffs to define underweight (<18.5 
kg/m), normal weight (18.5-24.9 kg/m), overweight (25.0-29.9 kg/m) and obesity 
(≥30kg/m). Waist circumference (WC) cutoffs to indicate increased risk of cardiovascular 
disease (CVD) were set at >88 cm in women and >102 cm in men. In November 2013, an 
update based on a systematic evidence review sponsored by NHLBI was released under the 
auspices of The American Heart Association, The American College of Cardiology and The 
Obesity Society entitled “Guideline for the Management of Overweight and Obesity in 
Adults”. Both reports presented algorithms to guide health care providers in making weight 
management recommendations with the ultimate goal of preventing or treating CVD.
The algorithms relied heavily on the opinions of expert panels, and there was no direct 
connection drawn between each element used to determine patients in need of treatment and 
supporting evidence. Variables used in both algorithms included BMI, WC and traditional 
CVD risk factors. Differences between the 1998 and 2013 algorithms related to the choice, 
definitions and number of risk factors used to determine groups to be recommended for 
weight loss. Neither report, nor any other publication known to us, has presented CVD risk 
estimates for each of the categories of patients specified to be treated or untreated according 
to either algorithm. This information would contribute insight into the potential of the 
guidelines to impact CVD risk in the American population. The purpose of this study was to 
estimate the incidence of fatal and nonfatal CVD in Black and White adults by weight loss 
treatment recommendation according to the two algorithms using data from the 
Atherosclerosis Risk in Communities (ARIC) Study cohort.
 Methods
Data for these analyses are from the ARIC study, a prospective, multi-center investigation of 
atherosclerosis in 15,792 Black and White men and women aged 45-64 years sampled from 
four US communities (Forsyth County, NC; Jackson, MS; Forsyth County, NC; 
Minneapolis, MN; and Washington County, MD) . Approximately 46% of the eligible 
participants in Jackson and 65% in the other three communities entered the cohort . Baseline 
data were collected in 1987-1989. The study was approved by the Institutional Review 
Boards (IRB) of the four field centers and the Coordinating Center; this analysis was 
approved by the IRB of the University of North Carolina at Chapel Hill.
Body weight was measured to the nearest pound using a beam balance scale with 
participants wearing a scrub suit. Height was measured to the nearest centimeter using a 
metal ruler attached to a wall and a standard triangular headboard with participants wearing 
no shoes. WC was measured at the level of the umbilicus with a metal or plastic tape to the 
nearest centimeter with the participant standing. Cardio-metabolic risk factors were 
measured using standard techniques .
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 Population subsets recommended for weight loss treatment
We used algorithms in the 1998 and the 2013 guidelines to categorize participants into those 
who were recommended for weight loss treatment and those who were not (Table S1). The 
1998 guidelines recommended treatment for motivated adults with the following 
characteristics: (1) with obesity (BMI ≥30 kg/m); (2) overweight (BMI 25.0-29.9 kg/m) plus 
≥2 CVD risk factors; or (3) high WC (>102 cm for men and >88 cm for women) plus ≥2 
CVD risk factors. Risk factors included age (men: ≥45 years; women: ≥55 years or 
postmenopausal), smoking, hypertension (≥140/90 mmHg or use of antihypertensive 
medication), LDL-cholesterol ≥160 mg/dl or use of lipid-lowering medication, HDL-
cholesterol <35 mg/dl, fasting glucose ≥110 mg/dl or use of hypoglycemic medication, and 
family history of premature coronary heart disease (CHD: definite myocardial infarction 
(MI) or death from heart attack at ≤55 years of age in father or other male first-degree 
relative, or ≤65 years of age in mother or other female first-degree relative).
The 2013 guidelines recommended weight loss for adults who are: (1) with obesity; or (2) 
overweight plus ≥1 CVD risk factor(s) or other obesity-related comorbidities. We did not 
include other obesity-related comorbidities because no clear definition was provided in the 
2013 guidelines. CVD risk factors included: type 2 diabetes mellitus (here defined as fasting 
glucose ≥126 mg/dl or use of hypoglycemic medication), prediabetes (here defined as 
fasting glucose ≥100 to <126 mg/dl), hypertension (≥140/90 mmHg or use of 
antihypertensive medication), dyslipidemia (total cholesterol ≥240 mg/dl, LDL-cholesterol 
≥160 mg/dl, HDL-cholesterol <40 mg/dl for men and <50 mg/dl for women, triglycerides 
≥200 mg/dl or use of lipid-lowering medication), and high WC (>102 cm for men and >88 
cm for women). More details on risk factor cutoffs are available elsewhere .
 Ascertainment of incident CVD
CVD was defined as first-onset of fatal or non-fatal CHD event or ischemic stroke. CHD 
included cardiac death and nonfatal MI, silent MI and coronary procedures. We performed 
separate analyses excluding silent MIs and/or procedures, and similar patterns were 
observed. To ascertain incident cases, ARIC staff annually contacted partitipants' homes by 
phone, surveyed discharge lists from local hospitals and local obituaries, and reviewed vital 
statistics,. Hospital charts were reviewed and abtracted, and death certificates were obtained. 
CHD and ischemic stroke were classified according to International Classification of 
Disease, Ninth Revision, and final determinations were adjudicated by cardiovascular 
experts. Participants were followed for events from baseline through December 31, 2011 and 
median follow-up time was 22.8 years.
 Analytic sample
Per ARIC standard protocol, we excluded Blacks from Washington County or Minneapolis 
(n = 55) and participants who were not White or Black (n = 48) from the 15,792 
participants. After excluding participants who were underweight (n=142), missing 
information on BMI or any CVD risk factors (n=1,008), had prevalent CHD or stroke 
(n=1,180), 13,359 individuals were included in the analysis.
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We used age as the time scale and handled left truncation by adjusting the risk set, such that 
a participant was considered at risk for CVD at age t when he or she had not had a CVD 
event and was in the study at that age. We compared hazard ratios (HRs) for incident CVD 
across groups defined in the 1998 and 2013 guidelines using Cox proportional hazards 
regression models. The proportional hazards assumptions were tested and satisfied by 
visually examining the Kaplan-Meier Curves and the graphs of the log(-log(survival)) versus 
log of age at event or censor for each categorical variable. Primary models were adjusted for 
gender, race and field center. In order to keep the reference category consistent across all our 
analyses, we used participants with obesity as the reference as they were uniformly 
designated to be treated by both algorithms. To examine whether the HRs for the hazard in 
untreated relative to treated differed between the two guidelines, we tested the interaction 
between indicators identifying the guideline used (1998 or 2013) and the designated 
treatment group (treated or untreated) in a proportional marginal hazard model for clustered 
data adjusting for covariates. Each participant contributed two observations to the data set, 
one for the 1998 and one for the 2013 guideline. The two observations from the same 
participant were treated as a cluster, and a robust variance was used to take into account the 
correlation within a cluster. Analyses were performed using SAS, (version 9.4, SAS 
Institute, Cary, USA).
 Results
Participants were on average 54.0 years of age, and the average BMI was within the 
overweight category (27.7 kg/m) (Table 1). BMI and WC tended to be highest in Black 
women and lowest in White women. Given that the intended age range in the ARIC cohort 
at baseline was 45 to 64, and that the age cutpoint named in the 1998 algorithm was >45 for 
men, essentially all men were in the older category. Blacks tended to have a higher 
prevalence of hypertension and diabetes and more favorable HDL-C levels compared to 
White of the same gender. Normal weight and overweight participants with more risk factors 
categories tended to be older at baseline(Table S2 and Table S3) and more likely to be 
smokers (Table S2) than those with fewer risk factors. Among those with ≥2 risk factors, 
normal weight participants had a greater prevalence of smoking compared to overweight 
participants (Table S2). Normal weight adults were less likely to have one or more cardio-
metabolic risk factor(s) than adults with overweight or obesity (defined using the 2013 
algorithm 69.9%, 91.2% and 99.5% in the 3 groups respectively). The overall crude 
incidence rate of CVD was 1,128 per 100,000 person-years. Up to 58.2% of participants 
were recommended for weight loss treatment by the 1998 guidelines, while this proportion 
was 63.0% for the 2013 guidelines. Fifty-four percent of participants were recommended for 
weight loss treatment by both algorithms (data not shown).
Figure 1 shows the HRs for the 9 subgroups defined by the 1998 algorithm adjusted for 
gender and ethnicity-field center. All 5 untreated groups were at lower risk of CVD 
compared to participants with obesity; however, normal weight-normal WC adults with ≥2 
risk factors were at higher risk (less protected) compared to similar participants with <2 risk 
factors. Combined, the treated group without obesity had a HR similar to that of the group 
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with obesity, and the untreated group had a lower HR (0.52, 95% CI: 0.47, 0.57). Less than 
2% of participants were normal weight - high WC with less than 2 risk factors, and with 
only 19 events, results in that group could be unstable.
HRs for CVD in the 5 subgroups defined by the 2013 algorithm are shown in Figure 2. CVD 
risk was lower in the combined untreated group compared to the group with obesity 
(HR=0.57, 95% CI: 0.52, 0.63), and also slightly lower in the treated group without obesity 
(HR=0.84, 95% CI: 0.77, 0.92). Among the three untreated groups shown in Figure 2, the 
normal weight with ≥1 risk factor(s) had the highest risk. Compared to participants with 
obesity, those recommended for weight loss by either or neither algorithm were at lower risk 
of CVD, with those recommended by the 2013 algorithm only having the lowest risk (HR: 
0.37, 95% CI: 0.31, 0.46) (Table S4).
The HRs for the combined groups designated to be untreated compared to those treated 
(reference) are also shown by race-gender groups in Table 2. The interaction analysis 
adjusted for demographic variables (Model 1) indicated slightly more protective effect for 
untreated relative to treated using the 1998 compared to the 2013 guidelines in overall 
participants, Black women, White women and White men (p <0.01 for all interactions). 
Further adjustment for smoking and family history of premature CHD (Model 2) attenuated 
the differences between the 1998 and the 2013 guidelines, but significant interactions 
remained in overall participants and Black women (p < 0.05 for both).
Race specific analyses that examined the 1998 guidelines showed effect modification 
indicating a lower (more protective) HR in Black women compared to Black men. This 
effect modification was seen in both models shown, but there were no gender interactions in 
Whites. Using the 2013 guidelines, there was no effect modification of the risk in the 
untreated compared to the treated by race or gender.
 Discussion
In our analysis, both the 1998 and 2013 guidelines identified subgroups of adults for weight 
loss treatment that were at increased risk of CVD, and the overall HRs for the untreated vs 
treated indicated that the 1998 algorithm performed slightly better than the 2013 in the 
models that adjusted for demographic variables (HR: 0.54 (95% CI: 0.50, 0.59) vs 0.63 
(95% CI: 0.58, 0.69) respectively). This difference was even smaller when models were 
additionally adjusted for family history of premature CHD and smoking: exposures known 
to increase CVD risk, which are not impacted by weight loss. We know of only one study 
that investigated different groups defined by the 1998 guidelines. Mason et al. examined 
18,666 men from the Aerobics Center Longitudinal Study after an average of 10.3 years of 
follow-up and found that compared to men not recommended for weight loss, those 
recommended for weight loss were at increased risk of all-cause mortality (HR: 1.46 
(95%CI: 1.20,1.78)) and CVD mortality (HR: 2.16 (95% CI: 1.53-3.04)). Although this 
study evaluated mortality rather than CVD events examined here, their results were 
consistent with our findings.
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In our examinations of the subgroups defined by the 1998 and 2013 algorithms we assigned 
the group with obesity to be the reference because all members of that group were 
recommended for treatment by both algorithms, and the common reference group facilitated 
comparisons. The reference group with obesity included adults with and without cardio-
metabolic risk factors, which is important to consider when making comparisons to groups 
without obesity stratified by risk factor status. If the reference group had been similarly 
stratified and composed only of participants with risk factors, there would have been greater 
discrepancies in risk between the reference and the untreated without obesity.
Three differences between the 1998 and 2013 algorithms are the application of WC, criteria 
for the number of CVD risk factors and the specific risk factors chosen for inclusion. The 
1998 algorithm used WC to determine recommendations for weight loss in normal weight 
individuals with ≥2 risk factors; whereas, in the 2013 algorithm a high WC influenced the 
assignment only in the overweight with no other risk factors. Our analysis of the 1998 
algorithm showed that normal weight individuals with ≥2 risk factors had about the same 
risk of CVD whether or not their WC was large. Using the 2013 algorithm, 9% of the 
overweight with ≥1 risk factor(s) had a high WC as their only risk factor. Since the 2013 
algorithm required only 1 risk factor in that group, these participants would be 
recommended for treatment by that algorithm, but might not be by the 1998 algorithm.
The 1998 algorithm listed more and somewhat different risk factors compared to the 2013 
version. As mentioned above, the 1998 algorithm included smoking and family history of 
premature CHD as risk factors, but the 2013 did not. In addition, the 1998 guidelines, but 
not the 2013 guidelines, included age as a risk factor placing greater emphasis on 
recommending weight loss in men over 45 years old and women over 55. Nevertheless, it 
has been shown that obesity in young adulthood is associated with increased risk of CVD, 
even after adjusting for subsequent weight change . In addition, up to at least the age of 75 , 
the difference in the absolute number of CVD deaths in the normal weight compared to 
participants with obesity is larger in older than younger adults, although the relative risk 
follows the opposite trend. This dichotomy is driven by the much higher rates of mortality in 
older compared to younger adults at every BMI level (including normal weight), and the 
impact of the uniformly higher death rates on estimates based on ratios compared to 
differences . Given all these issues, inclusion of age as a factor to indicate need for weight 
loss is not well justified. In fact, it may be better justified to alter the algorithm such that 
adults in old age (>80 years) would be less likely rather than more likely to be recommended 
for weight loss .
The 1998 algorithm provided clear definitions and cutoffs for cardio-metabolic risk factors 
including hypertension, impaired glucose tolerance, diabetes and high WC, but cut offs for 
dyslipidemia were less clear. In contrast, none of the cardio-metabolic risk factors were 
defined with operational precision in the report of the 2013 guidelines, and therefore our 
analysis relied on cutoffs cited by other expert groups. More detailed definitions would be 
helpful to researchers and may also assist health care providers, although it could be argued 
that the 2013, more general approach allows flexibility as new guidance on risk factors is 
released. We note that the recent controversy involving age and blood pressure cutpoints 
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does not impact the analysis here because the debate concerns identification of patients for 
pharmaceutical treatment of hypertension rather than the definition of hypertension , .
The intent of both obesity guidelines was to give primary care providers guidance on weight 
management decisions to reduce and prevent increased risk of CVD and obesity-related 
conditions. Inherent in this goal is not just identification of patients at increased CVD risk, 
but also identification of patients who will benefit from weight loss. The analyses presented 
here addressed only the first of these two goals. The recent review of meta-analyses and 
systematic reviews by members of the 2013 obesity guidelines expert committee supported 
the usefulness of weight loss in patients with overweight and obesity to reduce risk factors.
They concluded that weight reduction of 5-10% with lifestyle treatment lowered risk of 
developing type 2 diabetes, improved levels of HbA1c, triglycerides, LDL-C and blood 
pressure and reduced the need for diabetes medication.
Nevertheless, the only large randomized trial to examine the effects of voluntary weight loss 
on CVD events resulted in null findings. In the Look AHEAD trial, more than 5,000 
participants with type 2 diabetes were randomized into an intensive lifestyle intervention to 
promote weight loss or a diabetes support and education control group. After a median 
follow-up of 9.6 years, CVD rates were not reduced in the treatment compared to control 
group although several CVD risk factors were improved.
It is difficult to reconcile the impact of weight loss on CVD risk factor reduction with mixed 
evidence on CVD events. Evidence from previous studies is strong that elevated BMI is 
associated with increased risk factors, and that risk factors increase CVD rates . Also, the 
beneficial effects of weight loss on traditional CVD risk factors is well documented, and 
there is evidence that weight reduction through bariatric surgery is associated with a 
decrease in CVD events in subjects with obesity . However, evidence to support an effect of 
non-surgical intentional weight loss on CVD events is weak. The complex interplay between 
BMI, risk factors and CVD could involve the duration of elevated BMI and cardiometabolic 
risk factor exposures. Also, there could be residual deleterious effects of elevated risk factors 
that are not entirely resolved by their reduction. These possibilities point to the importance 
of prevention of risk factor development and, thus, suggest a potential value of weight loss in 
overweight adults with no risk factors; a group not recommended for treatment in either set 
of guidelines.
The 2013 guidance on management of overweight and obesity was part of a more 
comprehensive, long-term effort by NHLBI to provide evidence-based guidelines to promote 
CVD prevention in adults by periodically convening expert panels in critical areas. Review 
of the evidence to produce the 2013 obesity guidelines was conducted concurrently with 
reviews targeting blood cholesterol , lifestyle and risk assessment. Additionally, the 2014 
Evidence-Based Guideline for the Management of High Blood Pressure in Adults,was 
released by members appointed to the Eighth Joint National Committee (JNC8). Since the 
release of the 5 sets of most recent guidelines, several studies have been published that 
evaluated potential impact of these guidelines in a Western population,-. One of these 
addressed the obesity guidelines and found that approximately 60%, or 133 million 
American adults were candidates for weight loss treatment according to the 2013 obesity 
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guidelines, an increase of 20.9% over the previous guideline. No other study has compared 
the observed risk of CVD events by weight loss treatment recommendations as stipulated by 
the new compared to the previ ous obesity guidelines, as we have done here.
Limitations of our study include lack of information on primary health providers' 
recommendations for weight loss and participant's intentional weight change, and therefore 
we cannot evaluate the association between a recommendation for weight loss and CVD 
risk. Further, we excluded patients who had a CVD event before the baseline examination 
from our analysis, thus our findings are not applicable to those patients. The research base 
used by the Guidelines Committee examined incidence of first event, and so our approach is 
consistent with the data reviewed. Our study has several strengths. The ARIC study is a 
biracial cohort representing diverse communities in the US.Other strengths include 
laboratory measurements of risk factors, a long period of follow-up (22.8 years) and 
carefully adjudicated CVD events determined using multiple sources of information 
including hospital records.
Ideally trial evidence would be generated to estimate the impact of implementation of the 
entire set of the five 2013 guidelines intended to assist caregivers in the prevention of CVD 
in their patients. Unfortunately, a definitive randomized trial with that goal is not feasible, 
and therefore researchers need to continue to generate useful, albeit imperfect, evaluations 
using observational data. Analyses such as those described here are needed by policy makers 
who will likely continue to weave together information from multiple types of research and 
expert opinion to evaluate the success or failure of the 2013 guidelines for the prevention of 
CVD and the promotion of health.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Guidelines were released in 1998 and updated in 2013 to help primary care 
providers identify patients in need of weight loss in order to reduce 
cardiovascular risk.
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What this study adds
• Adults not recommended for weight loss were at lower risk of 
cardiovascular disease than adults recommended for weight loss, regardless 
of which guideline was used.
• Although risk of cardiovascular disease was similar in Blacks and Whites 
using the 1998 and the 2013 guidelines, in Blacks the gender difference in 
risk according to treatment assignment was reduced using the newer 
guidelines.
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Hazard ratios for cardiovascular disease by BMI, waist circumference and CVD risk factor 
categories defined in the 1998 Clinical Guidelines Open squares and closed squares 
represent 2 separate models using the category with obesity as reference. * Risk factors are 
age, smoking, family history of premature CHD, hypertension, high LDL-C, low HDL-C 
and diabetes. ** Adjusted for race-field center and gender.
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Hazard ratios for cardiovascular disease by risk factor categories defined in the 2013 
Clinical Guidelines Open squares and closed squares represent 2 separate models using the 
category with obesity as reference. * Risk factors are hypertension, dyslipidaemia, pre-
diabetes, diabetes, and high waist circumference. ** Adjusted for race-field center and 
gender.
Stevens et al. Page 14



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Obesity (Silver Spring). Author manuscript; available in PMC 2017 July 01.
